MMR vaccine and idiopathic thrombocytopaenic purpura.

AIMS To estimate the relationship between idiopathic thrombocytopaenic purpura (ITP) and the measles, mumps and rubella (MMR) vaccination in children; calculating the relative risk estimate for ITP with in 6 weeks after MMR vaccination and the attributable risk of ITP within 6 weeks after MMR vaccination. METHODS Using the General Practice Research Database we identified children with a first-time diagnosis of ITP from a base population of children aged less than 6 years between January 1988 and December 1999. After describing the characteristics of all the children identified with ITP, we focused on cases aged 13-24 months to perform a population-based, case-control analysis to estimate the relative risk of developing ITP within 6 weeks after MMR vaccination. We also calculated the risk of ITP attributable to the MMR vaccination. RESULTS Sixty-three children with a first time diagnosis of ITP were identified; 23 cases were between 13 and 24 months old. The relative risk estimate for ITP within 6 weeks after MMR vaccination, compared to the combined group of unvaccinated children and children vaccinated with MMR more than 26 weeks previously was 6.3 (95% CI 1.3-30.1). The attributable risk of developing ITP within 6 weeks after MMR vaccination was estimated to be 1 in 25,000 vaccinations (95% confidence interval 21,300, 89,400). CONCLUSION This study confirms the increased risk of ITP within 6 weeks after MMR vaccination. However, the attributable risk of ITP within 6 weeks after MMR vaccination is low.

[1]  H Jick,et al.  Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. , 1991, BMJ.

[2]  F. Varricchio,et al.  Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). , 1996, The Pediatric infectious disease journal.

[3]  Kenneth Dougan,et al.  Acute Idiopathic Thrombocytopenic Purpura Following Combined Vaccination Against Measles, Mumps, and Rubella , 1996, The Journal of the American Board of Family Medicine.

[4]  C P Farrington,et al.  Idiopathic thrombocytopenic purpura and MMR vaccine , 2001, Archives of disease in childhood.

[5]  H Jick,et al.  Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis , 2001, BMJ : British Medical Journal.

[6]  J. Winiarski.  Mechanisms in childhood idiopathic thrombocytopenic purpura (ITP) , 1998, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[7]  H. Jick.  A database worth saving , 1997, The Lancet.

[8]  D. Miron,et al.  Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. , 1996, Pediatrics.

[9]  P. Tazzari,et al.  Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine , 1998, Archives of disease in childhood.

[10]  H. Jick,et al.  Haemophilus influenzae vaccine. , 1995, The British journal of general practice : the journal of the Royal College of General Practitioners.

[11]  E. Autret,et al.  Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins. , 1996, The Pediatric infectious disease journal.

[12]  Susan S. Jick,et al.  Further validation of information recorded on a general practitioner based computerized data resource in the united kingdom , 1992 .